Literature DB >> 7985803

Kinetic applications using high substrate and competitive inhibitor concentrations to determine Ki or Km.

K Tornheim1.   

Abstract

Conventional procedures for determining Km or Ki values generally employ subsaturating concentrations of substrate and competitive inhibitor; however, this is impractical in some cases if a significant percentage would be enzyme-bound or metabolized. Applications employing high and competing concentrations of substrates and inhibitors are described. Ki or Km values can be calculated from the equations. Ki = [I]/((V0)/V - 1)(1 + [S]/Km)) Km = [S](V0/V - 1)/(1 - V0/V + [I]/Ki), where V0 and V are the rates in the absence and presence of inhibitor. This is illustrated by measurements of inhibition of human urinary kallikrein by synthetic peptides.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7985803     DOI: 10.1006/abio.1994.1377

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  4 in total

1.  EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.

Authors:  Michael T McCabe; Heidi M Ott; Gopinath Ganji; Susan Korenchuk; Christine Thompson; Glenn S Van Aller; Yan Liu; Alan P Graves; Anthony Della Pietra; Elsie Diaz; Louis V LaFrance; Mark Mellinger; Celine Duquenne; Xinrong Tian; Ryan G Kruger; Charles F McHugh; Martin Brandt; William H Miller; Dashyant Dhanak; Sharad K Verma; Peter J Tummino; Caretha L Creasy
Journal:  Nature       Date:  2012-10-10       Impact factor: 49.962

2.  Pimelic diphenylamide 106 is a slow, tight-binding inhibitor of class I histone deacetylases.

Authors:  C James Chou; David Herman; Joel M Gottesfeld
Journal:  J Biol Chem       Date:  2008-10-24       Impact factor: 5.157

3.  Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation.

Authors:  Marjo J Karjalainen; Pertti J Neuvonen; Janne T Backman
Journal:  Eur J Clin Pharmacol       Date:  2007-07-06       Impact factor: 2.953

4.  Balancing Histone Deacetylase (HDAC) Inhibition and Drug-likeness: Biological and Physicochemical Evaluation of Class I Selective HDAC Inhibitors.

Authors:  Linda Schäker-Hübner; Reza Haschemi; Thomas Büch; Fabian B Kraft; Birke Brumme; Andrea Schöler; Robert Jenke; Jens Meiler; Achim Aigner; Gerd Bendas; Finn K Hansen
Journal:  ChemMedChem       Date:  2022-02-18       Impact factor: 3.540

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.